IM Cannabis (IMCC) Free Cash Flow Growth (3y) (2023 - 2026)
IM Cannabis (IMCC) Free Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.48 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 39.19% |
| 10 | IM Cannabis | 530,175.99 | -201,946.53 | 1.03 Mn | 68.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.39% |
| Dec 31, 2025 | 55.33% |
| Sep 30, 2025 | -70.59% |
| Jun 30, 2025 | 26.38% |
| Mar 31, 2025 | 34.80% |
| Dec 31, 2024 | -47.35% |
| Sep 30, 2024 | 28.53% |
| Jun 30, 2024 | 27.36% |
| Mar 31, 2024 | 55.92% |
| Dec 31, 2023 | -84.56% |
| Sep 30, 2023 | 74.24% |
| Jun 30, 2023 | -36.75% |
| Mar 31, 2023 | -69.19% |